OnKure Therapeutics Reports First Quarter 2026 Financial Results
OnKure Therapeutics reported Q1 2026 financial results, highlighting a strengthened balance sheet with $192.1 million in cash following a $150 million private placement that closed in March. The company announced the nomination of two next-generation PI3Kα pan-mutant selective inhibitor candidates, OKI-355 for vascular anomalies and OKI-345 for breast cancer, with IND submissions planned for the first half of 2027.
Key figures
- Revenue
- 0
- Guidance
- Cash runway expected to fund operations into 2029; IND submissions for OKI-355 and OKI-345 planned for first half of 2027
- Net loss
- 15157000
- Ga expenses
- 3900000
- Rd expenses
- 11700000
- Cash and equivalents
- 192106000
- Private placement proceeds
- 150000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.